Neeraj Agarwal, MD
Dr. Neeraj Agarwal is a Professor of medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.
Dr. Agarwal is an internationally recognized physician scientist in the field of genitourinary cancers. He is the overall study chair of multiple Phase I/II and Phase III trials, and serves as a steering committee member of numerous other trials. He has received SWOG Young Investigator Award, the William D. Odell Young Investigator Award, and a National Cancer Institute Cancer Clinical Investigator Team Leadership Award. After receiving his medical training at the All India Institute of Medical Sciences in New Delhi, he completed a residency in internal medicine and a fellowship in geriatric medicine at the University of Iowa, followed by a hematology-oncology fellowship at HCI.
Dr. Agarwal has authored more than 350 peer-reviewed articles and book chapters. He serves as a panel member for the NCCN guideline committees for bladder and kidney cancers. He is an advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, and leads early therapeutics in the SWOG genitourinary cancers committee. He holds numerous scientific communications leadership roles, including chief editor of the ASCO Daily News, specialty editor for ASCO’s cancer.net site, and editorial board member of several journals, including Journal of Clinical Oncology and European Urology. He also serves as a member of the ASCO Genitourinary Cancers Advisory Panel. Recently, Dr. Agarwal was appointed as the Senior Director for Clinical Research Innovation, directly reporting to the cancer center director at the Huntsman Cancer Institute.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:Aveo, Bayer, Bristol Myers Squibb, Calithera, Eli Lilly, Exelixis, Genentech, Gilead, Merck, MEI Pharma,Topic:Consultancy on scientific ad boardDate added:10/05/2022Date updated:10/05/2022